.
A new blood test that can detect more than 50 types of cancer in a single blood draw is now available in the United States with a prescription.
And it’s all thanks to a biotech firm with strong ties to the Triangle.
The test, called Galleri, is developed by the California-based biotech firm GRAIL, which is building a manufacturing facility in Research Triangle Park.
With a list price of $949, it’s being hailed as “groundbreaking.”
“Finding cancer early, when treatment is more likely to be successful, is one of the most significant opportunities we have to reduce the burden of cancer,” said Joshua Ofman, M.D., chief medical officer and head of external affairs at GRAIL.
by Jim Shamp, NCBiotech writer April 21, 2021 .
Editor’s note: Each Wednesday, WRAL TechWire features a story highlighting life science jobs across North Carolina and the NC Bio Jobs Hub initiative from the North Carolina Biotechnology Center.
DURHAM – Soon you might run into it anywhere around the Triangle:
“Me? Oh, I just started working at the GRAIL plant in RTP.”
“Somehow I never pictured you working in manufacturing.”
“Um…we make cancer detection kits. Really special kits. They could save your life. Or mine. So yes. It’s great. This is manufacturing work like none other.”
GRAIL, an innovative California healthcare company, announced last June that it would invest $103 million and create nearly 400 new jobs over four years in a new 200,000-square-foot lab, office, and warehouse facility in Research Triangle Park.